Cargando…
Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018920/ https://www.ncbi.nlm.nih.gov/pubmed/36927387 http://dx.doi.org/10.1186/s12943-023-01754-6 |
| _version_ | 1784907913406447616 |
|---|---|
| author | Lee, Ho Jin Pham, Phuong Chi Hyun, Seung Yeob Baek, Byungyeob Kim, Byungjin Kim, Yunha Min, Hye-Young Lee, Jeeyeon Lee, Ho-Young |
| author_facet | Lee, Ho Jin Pham, Phuong Chi Hyun, Seung Yeob Baek, Byungyeob Kim, Byungjin Kim, Yunha Min, Hye-Young Lee, Jeeyeon Lee, Ho-Young |
| author_sort | Lee, Ho Jin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10018920 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100189202023-03-17 Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity Lee, Ho Jin Pham, Phuong Chi Hyun, Seung Yeob Baek, Byungyeob Kim, Byungjin Kim, Yunha Min, Hye-Young Lee, Jeeyeon Lee, Ho-Young Mol Cancer Correction BioMed Central 2023-03-08 /pmc/articles/PMC10018920/ /pubmed/36927387 http://dx.doi.org/10.1186/s12943-023-01754-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Lee, Ho Jin Pham, Phuong Chi Hyun, Seung Yeob Baek, Byungyeob Kim, Byungjin Kim, Yunha Min, Hye-Young Lee, Jeeyeon Lee, Ho-Young Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity |
| title | Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity |
| title_full | Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity |
| title_fullStr | Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity |
| title_full_unstemmed | Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity |
| title_short | Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity |
| title_sort | correction: development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual igf1r/src inhibitor as a novel anticancer agent with minimal toxicity |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018920/ https://www.ncbi.nlm.nih.gov/pubmed/36927387 http://dx.doi.org/10.1186/s12943-023-01754-6 |
| work_keys_str_mv | AT leehojin correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity AT phamphuongchi correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity AT hyunseungyeob correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity AT baekbyungyeob correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity AT kimbyungjin correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity AT kimyunha correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity AT minhyeyoung correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity AT leejeeyeon correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity AT leehoyoung correctiondevelopmentofa4aminopyrazolo34dpyrimidinebaseddualigf1rsrcinhibitorasanovelanticanceragentwithminimaltoxicity |